Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
Learn more about:
Related Clinical Trial
Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis
Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
Tebipenem Trial in Children With Shigellosis
Controlled Human Infection Model Challenge/Rechallenge
Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers
Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Administered Intranasally to Healthy, Adult Volunteers
Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a
Therapeutic Induction of Endogenous Antibiotics
A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
Shigella Sonnei OSPC-rDT Conjugate Vaccine
Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults
Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella
Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a
Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel
Shigella Sonnel O-SPC/rBRU Conjugate Vaccine
Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection